Browsing Faculty of Health Sciences (FHS) by Author "Qureshi, Z.P"
Now showing items 1-13 of 13
-
Advance provision of oral contraceptives to family planning clients in Kenya.
Stanback, J; Qureshi, Z.P; Sekkade-Kigondu, C (2002)In sub-Saharan Africa, many family planning programmes do not encourage advance provision of oral contraceptives to clients who must wait until menses to initiate pill use. Since some resistance to advance provision of ... -
Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States.
Qureshi, Z.P; Norris, L; Sartor, O; McKoy, J.M; Armstrong, J; Raisch, D.W; Garg, V; Stafkey-Mailey, D; Bennett, C.L (2012)Counterfeit pharmaceuticals pose risks domestically. Because of their cost, cancer pharmaceuticals are vulnerable. We review findings from a domestic counterfeiting episode involving erythropoietin and outline anticounterfeiting ... -
Current management of hypertensive disease in pregnancy.
Qureshi, Z.P (2002) -
Enforcement actions involving Medicaid fraud and abuse, 1996-2009.
Qureshi, Z.P; Liu, Y; Sartor, O; Chu, Y.H; Bennett, C.L (2011) -
Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.
Bennett, C.L; Qureshi, Z.P; Sartor, A.O; Norris, L.B; Murday, A; Xirasagar, S; Thomsen, H.S (2012)In 2006, nephrologists in Denmark unexpectedly identified chronic kidney disease (CKD) patients with a new syndrome, nephrogenic systemic fibrosis (NSF). Subsequently, 1603 NSF patients were reported to the Food and Drug ... -
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).
Bennett, C.L; Starko, K.M; Thomsen, H.S; Cowper, S; Sartor, O; Macdougall, I.C; Qureshi, Z.P; Bookstaver, P.B; Miller, A.D; Norris, L.B; Xirasagar, S; Trenery, A; Lopez, I; Kahn, A; Murday, A; Luminari, S; Cournoyer, D; Locatelli, F; Ray, P; Mattison, D.R (2012)Identification of serious adverse drug reactions (sADRS) associated with commonly used drugs can elude detection for years. Reye's syndrome (RS), nephrogenic systemic fibrosis (NSF), and pure red cell aplasia (PRCA) among ... -
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
Qureshi, Z.P; Seoane-Vazquez, E; Rodriguez-Monguio, R; Stevenson, K.B; Szeinbach, S.L (2011)Economic factors, market dynamics, and safety issues are largely responsible for decisions to withdraw pharmaceutical products from the market. In this study, new molecular entities (NMEs) approved by the Food and Drug ... -
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).
Bennett, C.L; Spiegel, D.M; Macdougall, I.C; Norris, L; Qureshi, Z.P; Sartor, O; Lai, S.Y; Tallman, M.S; Raisch, D.W; Smith, S.W; Silver, S; Murday, A.S; Armitage, J.O; Goldsmith, D (2012)The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor ... -
Safe motherhood in Africa: achievable goal or a dream?
Qureshi, Z.P (2005) -
A survey on the knowledge and attitudes of men in Machakos town towards vasectomy.
Qureshi, Z.P; Solomon, M.M (1995)In November and December, 1993, a self-administered questionnaire was distributed to men in the town of Machakos and to nonmedical hospital workers of Machakos General Hospital. The purpose of the study was to assess their ... -
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.
Chen, B; Restaino, J; Norris, L; Xirasagar, S; Qureshi, Z.P; McKoy, J.M; Lopez, I.S; Trenery, A; Murday, A; Kahn, A; Mattison, D.R; Ray, P; Sartor, O; Bennett, C.L (2012)Pharmaceutical safety is a public health issue. In 2005, the Connecticut Attorney General (AG) raised concerns over adverse drug reactions in off-label settings, noting that thalidomide was approved to treat a rare illness, ... -
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
Jacob, S; Dunn, B.L; Qureshi, Z.P; Bandarenko, N; Kwaan, H.C; Pandey, D.K; McKoy, J.M; Barnato, S.E; Winters, J.L; Cursio, J.F; Weiss, I; Raife, T.J; Carey, P.M; Sarode, R; Kiss, J.E; Danielson, C; Ortel, T.L; Clark, W.F; Rock, G; Matsumoto, M; Fujimura, Y; Zheng, X.L; Chen, H; Chen, F; Armstrong, J.M; Raisch, D.W; Bennett, C.L (2012)Thienopyridine-derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the ... -
Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).
Bennett, C.L; Jacob, S; Dunn, B.L; Georgantopoulos, P; Zheng, X.L; McKoy, J.M; Magwood, J.S; Qureshi, Z.P; Bandarenko, N; Winters, J.L; Raife, T.J; Carey, P.M; Sarode, R; Kiss, J.E; Danielson, C; Ortel, T.L; Clark, W.F; Ablin, R.J; Rock, G; Matsumoto, M; Fujimura, Y (2013)